Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05300048 · ClinicalTrials.gov registry record · Phase 1
Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
A Phase 1 study, sponsored by Faeth Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT05300048 is a Phase 1 study that was terminated before completion, run by Faeth Therapeutics. The registered enrollment target is 34 participants.
The verdict
NCT05300048, a Phase 1 study, was terminated before completion, sponsored by Faeth Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined with an ISD and with or without nab-paclitaxel with a goal of reducing side effects and enhancing anticancer activity.
Interventions
- DRUG Nab paclitaxel
- DRUG Serabelisib
- OTHER Insulin Suppressing Diet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2022-04-22 |
| Est. Completion | 2025-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05300048
The ClinicalTrials.gov registry entry for NCT05300048 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Faeth Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nab paclitaxel is the first listed.
NCT05300048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05300048 about?
NCT05300048 is a clinical study titled "Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations". This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined with an ISD and with or without nab-paclitaxel with a goal of reducing side effects and enhancing anticancer activity.
What is the current status of trial NCT05300048?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2022-04-22. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT05300048?
The interventions under investigation include: Nab paclitaxel (DRUG), Serabelisib (DRUG), Insulin Suppressing Diet (OTHER).
Who is sponsoring clinical trial NCT05300048?
This trial is sponsored by Faeth Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.